Your sister gets migraines a few times a month. A wellness clinic and a research-peptide website both talk up VIP, a messenger peptide found in the gut and the nerves around the head, as a calming anti-inflammatory. Before she tries anything, she wants to know one thing: could VIP set off a migraine?
In controlled hospital experiments, yes. At the Danish Headache Center in Copenhagen, a two-hour infusion of VIP into a vein triggered migraine attacks in 15 of 21 people with migraine, compared with 1 of 21 after a placebo infusion. Shorter infusions in earlier studies had not done that. None of this research tested a nasal spray or a research-catalog product, but it is the most direct human evidence that VIP can provoke attacks in people who are prone to them.
How headache researchers test a suspected trigger
Headache scientists use what they call provocation studies. Volunteers receive a substance or a dummy infusion on separate days, neither they nor the staff know which, and everyone records headaches for the next 12 hours. The same approach helped show that CGRP, the target of several newer migraine drugs, can start attacks.
The first VIP tests were short. In 2006, Hansen and colleagues gave 12 healthy young volunteers a 25-minute infusion. Five reported a headache after VIP and one after placebo, but it was very mild, peaking at 2 on a 10-point scale. The scalp artery at the temple widened and heart rate rose, then both settled within about half an hour.
Rahmann and colleagues then repeated the short test in 12 people who have migraine without aura. VIP clearly widened the arteries of the head, yet no one had a migraine attack. Delayed headaches were about as common after VIP as after placebo. The authors read this as evidence that widening blood vessels alone does not explain migraine.
What changed when the infusion lasted two hours
Researchers suspected the short tests ended before VIP had time to act. In a 2020 study, Pellesi and colleagues gave 12 healthy volunteers a two-hour infusion. This time the temple artery stayed wider for more than two hours after the drip stopped, tear production rose, and headaches were more common than on the placebo day, mostly mild ones that arrived hours later.
The 2021 trial in JAMA Network Open was the decisive one. Twenty-one adults aged 18 to 40 with migraine without aura, 17 of them women, each received the two-hour VIP infusion and a placebo on different days in random order. Seventy-one percent had a migraine attack after VIP, against five percent after placebo, and the attacks resembled their usual ones. Two of the authors worked for the drug company Novartis, and the team suggested VIP receptors as a target for future migraine drugs.
Cluster headache, a different and very painful condition, showed a similar pattern. In a 2020 study by Vollesen and colleagues, a short VIP infusion set off cluster-like attacks in 5 of 14 people in an active cluster period and 7 of 15 with chronic cluster headache, but in no one whose cluster headaches were in remission.
What a person with migraines can take from this
These were tightly controlled intravenous infusions in a hospital, so they do not tell you exactly what a nasal spray or any other form would do. Most volunteers were young adults without other major illnesses. Taken together, the studies suggest that longer exposure to VIP can trigger attacks in people with migraine, and cluster attacks in people in an active cluster period. Online research-chemical VIP vials carry a not-for-human-use label, were never part of these experiments, and this evidence gives no reason to try one.
If you live with migraine or cluster headache and someone recommends VIP for another problem, bring these studies to your clinician and ask whether the possible trade-off is worth it. A headache diary helps too. MedlinePlus lists common triggers worth tracking, including stress, too much or too little sleep, skipped meals, some medicines, and taking migraine medicine too often. Not medical advice.
Sources
- Pellesi L et al. Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches: A Randomized Clinical Trial. JAMA Netw Open, 2021 (PubMed)
- Pellesi L et al. Two-hour infusion of vasoactive intestinal polypeptide induces delayed headache and extracranial vasodilation in healthy volunteers. Cephalalgia, 2020 (PubMed)
- Rahmann A et al. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia, 2008 (PubMed)
- Hansen JM et al. Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia, 2006 (PubMed)
- Vollesen ALH et al. The effect of PACAP38 and vasoactive intestinal peptide in cluster headache. Cephalalgia, 2020 (PubMed)
- MedlinePlus: Migraine
Related reading
- Label warnings to know before starting a CGRP migraine drug
- What 1980s inhaler tests found for VIP and asthma
- How hospital aviptadil trials differ from VIP research listings
By The Everyday Brief. AI-assisted drafting with automated source and editorial checks. Sources fetched 2026-10-23 PT. Not medical advice.